[Form 4] NovoCure Limited Insider Trading Activity

Rhea-AI Filing Summary

NovoCure (NVCR) insider purchase by CEO Ashley Cordova: The filing reports that on 09/05/2025 the reporting person purchased 81,550 ordinary shares in multiple trades at prices ranging from $12.02 to $12.47, with a weighted average price of $12.2239. After the purchases, the reporting person beneficially owned 437,569 shares. The Form 4 identifies Ashley Cordova as Chief Executive Officer and a director, and the filing was signed by an attorney-in-fact on 09/08/2025. The filer notes willingness to provide detailed trade-level prices and quantities on request.

Positive

• CEO and director purchased shares, increasing direct beneficial ownership to 437,569 shares
• Substantial open-market purchase of 81,550 shares at a weighted average price of $12.2239 signals management acquisition

Negative

• No disclosure of a 10b5-1 trading plan in the filing, so purchases were not identified as pre-planned under Rule 10b5-1
• Filing does not state total percentage ownership or company market-cap context, limiting assessment of materiality

Insights

Financial Analyst

TL;DR: Insider purchases 81,550 shares at ~$12.22 each, increasing holdings to 437,569 shares; a potentially constructive signal about management confidence.

The transaction is a cash purchase by the CEO and director executed in multiple trades, producing a modest but notable increase in direct ownership. The weighted average price reported is $12.2239 and the range was $12.02 to $12.47. For investors this is a factual disclosure of insider accumulation rather than forward guidance; its materiality depends on NovoCure's market capitalization and typical insider activity levels, which are not provided here.

Corporate Governance Expert

TL;DR: A documented open-market purchase by the CEO strengthens alignment with shareholders but contains no plan-based or derivative transactions.

The Form 4 shows direct purchases (transaction code P) with full acknowledgment that trade-level details can be supplied on request, consistent with transparent Section 16 reporting. There is no indication of a 10b5-1 plan checkbox checked, and no derivative activity reported. This is a routine insider disclosure reflecting personal purchase activity by a principal officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cordova Ashley

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/05/2025		P		81,550	A	$12.2239(1)	437,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On the transaction date, the reporting person purchased 81,550 shares in multiple trades at prices ranging from $12.02 to $12.47. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	Steven Robbins, as attorney in fact for Cordova, Ashley	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NovoCure (NVCR) insider Ashley Cordova do on 09/05/2025?

Ashley Cordova purchased 81,550 ordinary shares in multiple trades on 09/05/2025 at prices between $12.02 and $12.47, weighted average $12.2239.

How many shares does the reporting person own after the transaction?

437,569 shares beneficially owned following the reported purchases.

What is the transaction code and what does it mean?

Transaction code P indicates an open-market or private purchase of securities by the reporting person.

Was the purchase made under a 10b5-1 trading plan?

The filing does not indicate a 10b5-1 plan; the checkbox for plan-based transactions is not marked.

Who signed the Form 4 and when?

Steven Robbins, as attorney-in-fact for Ashley Cordova, signed the form on 09/08/2025.